Evaluation of individual sensitivity of head and neck squamous cell carcinoma to cetuximab by short‐term culture of tumor slices

Keywords

Cetuximab, Head and neck squamous-cell carcinoma, Medicine, Head and neck cancer, Immunohistochemistry

References

• Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.Corinne Godin, Sébastien Dupont, Zakaria Ezzoukhry — 2013
• Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environmentHeiko van der Kuip, Thomas E. Mürdter, Maike Sonnenberg — 2006
• EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenibZakaria Ezzoukhry, Christophe Louandre, E. Trécherel — 2012
• Preclinical model of organotypic culture for pharmacodynamic profiling of human tumorsValentina Vaira, Giuseppe Fedele, Saumyadipta Pyne — 2010
• Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.Vijaya Raj Bhatt, Apar Kishor Ganti — 2014
• Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistanceM. Gerlach, Felicitas Merz, Gunnar Wichmann — 2013
• Breast cancer tissue slices as a model for evaluation of response to rapamycinStana Helena Giorgi Grosso, Maria Lúcia Hirata Katayama, Rosimeire Aparecida Roela — 2013
• Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatmentsFelicitas Merz, Frank Gaunitz, Faramarz Dehghani — 2013
• Platinum-based chemotherapy plus cetuximab in head and neck cancer.Jan B. Vermorken, Ricard Mesı́a, Fernando Rivera — 2008
• The practicalities of using tissue slices as preclinical organotypic breast cancer modelsDeborah L. Holliday, Marcus A. Moss, Steven Pollock — 2012
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.James A. Bonner, Paul M. Harari, J. Giralt — 2010
• Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancerRenata Afonso Sobral, Suzana Terumi Honda, Maria Lúcia Hirata Katayama — 2008
• Mechanisms of resistance to EGFR inhibitors in head and neck cancerJ.B. Cooper, Ezra E.W. Cohen — 2009
• BASIC SCIENCE REVIEWJonathan A. Cooper, Ezra E. W. Cohen — 2009

Cited by

• Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative ReviewAmy J.C. Dohmen, Justin E. Swartz, Michiel W. M. van den Brekel — 2015
• Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor SpheroidsStephan Klöß, Nicole Chambron, Tanja Gardlowski — 2015
• Personalization of the medical treatment of solid tumours using patient-derived tumour explants (Review).Christophe Louandre, Jérôme Donnadieu, Emma Lachaier — 2016
• Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapiesJérôme Donnadieu, Emma Lachaier, M. Peria — 2016
• Präklinische Modelle für Kopf-Hals-TumorenAnnette Affolter, J. Hess — 2016
• Advanced head and neck cancer treatment: A basic step forwardAmy J.C. Dohmen — 2018
• Antitumoral Effect of Laurinterol on 3D Culture of Breast Cancer ExplantsSara García-Davis, Ezequiel Viveros‐Valdez, Ana R. Díaz‐Marrero — 2019
• Ex Vivo Culture Models to Indicate Therapy Response in Head and Neck Squamous Cell CarcinomaImke Demers, Johan Donkers, Bernd Kremer — 2020
• Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck CancerAnnette Affolter, Anne Lammert, Johann Kern — 2021
• Kinomic comparison of snap frozen and ex vivo-cultured head and neck tumors.Joanna Berger, Henrike Zech, Konstantin Hoffer — 2021
• CD44, γ-H2AX, and p-ATM Expressions in Short-Term Ex Vivo Culture of Tumour Slices Predict the Treatment Response in Patients with Oral Squamous Cell CarcinomaPierre Philouze, Arnaud Gauthier, Alexandra Lauret — 2022
• Functional Ex Vivo Tissue-Based Chemotherapy Sensitivity Testing for Breast CancerMarjolijn M. Ladan, Titia G. Meijer, Nicole S. Verkaik — 2022
• In vitro models as tools for screening treatment options of head and neck cancerBarbara Seliger, Ahmed Al‐Samadi, Bo Yang — 2022
• Recent advances in organotypic tissue slice cultures for anticancer drug developmentLin He, Chuxia Deng — 2022
• The organoid as reliable cancer modeling in personalized medicine, does applicable in precision medicine of head and neck squamous cell carcinoma?Alieh Farshbaf, Malihe Lotfi, Reza Zare — 2022
• In Vitro Models of Head and Neck Cancer: From Primitive to Most AdvancedI. V. Arutyunyan, Enar Jumaniyazova, А. В. Макаров — 2023
• Preclinical in vitro models of HNSCC and their role in drug discovery - an emphasis on the cancer microenvironment and microbiotaAnne‐Sophie Becker, Sonja Oehmcke-Hecht, Erik Dargel — 2024
• Tumor-associated macrophages in head and neck carcinoma: clinicopathological correlations and implications for immunotherapyDiane Evrard, Aurélie Beaufrère, Clément Dumont — 2026
• Präklinische Modelle für Kopf-Hals-Tumoren: Aufklärung zellulärer und molekularer Resistenzmechanismen im GewebekontextAnnette Affolter, Jochen Heß — 2016
• Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer ManagementAbby R. Templeton, Penny L. Jeffery, Patrick B. Thomas — 2021

Related papers

• The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination StrategyHannah Zaryouh, Ines De Pauw, Hasan Baysal — 2021
• Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinomaRachel A. O’Keefe, Neil E. Bhola, Toni M. Brand — 2017
• Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC)Ning Jiang, Dongsheng Wang, Zhongliang Hu — 2014
• Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell CarcinomaNing Jiang, Dongsheng Wang, Zhongliang Hu — 2023
• Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrcAdam Jedliński, Stina Garvin, Ann‐Charlotte Johansson — 2017
• SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cellsHiroyuki Ozawa, Ruchira S. Ranaweera, Evgeny Izumchenko — 2017
• Should cetuximab replace cisplatin in head and neck cancer?Karen Rowan — 2010
• Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinomaOlivia Leblanc, Sophie Vacher, Charlotte Lecerf — 2020